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Background
Early, goal-directed therapy (EGDT) is recommended in international guidelines for 
the resuscitation of patients presenting with early septic shock. However, adoption 
has been limited, and uncertainty about its effectiveness remains.
Methods
We conducted a pragmatic randomized trial with an integrated cost-effectiveness 
analysis in 56 hospitals in England. Patients were randomly assigned to receive 
either EGDT (a 6-hour resuscitation protocol) or usual care. The primary clinical 
outcome was all-cause mortality at 90 days.
Results
We enrolled 1260 patients, with 630 assigned to EGDT and 630 to usual care. By 
90 days, 184 of 623 patients (29.5%) in the EGDT group and 181 of 620 patients 
(29.2%) in the usual-care group had died (relative risk in the EGDT group, 1.01; 
95% confidence interval [CI], 0.85 to 1.20; P = 0.90), for an absolute risk reduction 
in the EGDT group of −0.3 percentage points (95% CI, −5.4 to 4.7). Increased treat-
ment intensity in the EGDT group was indicated by increased use of intravenous 
fluids, vasoactive drugs, and red-cell transfusions and reflected by significantly 
worse organ-failure scores, more days receiving advanced cardiovascular support, 
and longer stays in the intensive care unit. There were no significant differences in 
any other secondary outcomes, including health-related quality of life, or in rates of 
serious adverse events. On average, EGDT increased costs, and the probability that 
it was cost-effective was below 20%.
Conclusions
In patients with septic shock who were identified early and received intravenous 
antibiotics and adequate fluid resuscitation, hemodynamic management according 
to a strict EGDT protocol did not lead to an improvement in outcome. (Funded by the 
United Kingdom National Institute for Health Research Health Technology Assess-
ment Programme; ProMISe Current Controlled Trials number, ISRCTN36307479.)
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF BIRMINGHAM on January 19, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 372;14 nejm.org april 2, 20151302
The incidence of severe sepsis and septic shock in adults is estimated to range from 56 to 91 per 100,000 population per 
year.1 Affected patients have high rates of death, 
complications, and resource utilization.2-5
Since 2002, the Surviving Sepsis Campaign 
(SSC) has promoted best practice, including early 
recognition, source control, appropriate and timely 
antibiotic administration, and resuscitation with 
intravenous fluids and vasoactive drugs.6-8 Resus-
citation guidance is largely based on a 2001 single-
center, proof-of-concept study by Rivers et al., 
which indicated that protocolized delivery of 
6 hours of early, goal-directed therapy (EGDT) to 
patients presenting to the emergency department 
with early septic shock reduced hospital mortality 
and hospital stay.9 Such therapy aims to optimize 
tissue oxygen transport with the use of continu-
ous monitoring of prespecified physiological tar-
gets — central venous pressure, mean arterial 
pressure, and central venous oxygen saturation 
(ScvO2) — to guide delivery of intravenous flu-
ids, vasoactive drugs, and red-cell transfusions.
However, despite the SSC recommendations, 
the adoption of EGDT has been limited, with 
concern about the external validity of results 
from a single center, the complexity of delivery, 
the potential risks of the components, and re-
sources required for implementation.10,11
To address these concerns, multicenter trials of 
EGDT were conducted in the United States (Pro-
tocolized Care for Early Septic Shock [ProCESS] 
trial),12 Australasia (Australasian Resuscitation in 
Sepsis Evaluation [ARISE] trial),13 and England 
(Protocolised Management in Sepsis [ProMISe] 
trial). In all three trials, harmonized methods14 
were used to permit subsequent meta-analysis of 
data from individual patients.15 The two published 
studies12,13 reported no benefit for EGDT. How-
ever, both reported lower-than-anticipated mortal-
ity, with a 60-day in-hospital mortality of 18.9% 
(as compared with an anticipated rate of 30 to 
46%) in the ProCESS trial and 90-day mortality of 
18.8% (as compared with an anticipated rate of 
38%) in the ARISE trial. Consequently, neither 
trial could rule out the potential for a 20% relative 
reduction in 90-day mortality for EGDT, as com-
pared with usual care, with a relative risk of 0.94 
(95% confidence interval [CI], 0.77 to 1.15) in the 
ProCESS trial and a relative risk of 0.98 (95% CI, 
0.80 to 1.21) in the ARISE trial. We based sample-
size calculations for the ProMISe study on a rela-
tive risk reduction of 20%.
The ProMISe study, which was conducted in a 
setting in which the reported mortality for septic 
shock is high and was designed with an integrat-
ed economic evaluation, tested the hypothesis 
that the 6-hour EGDT resuscitation protocol is 
superior, in terms of clinical and cost-effective-
ness measures, to usual care in patients present-
ing with early septic shock to National Health 
Service (NHS) emergency departments in En-
gland.
Me thods
Study Design and Oversight
Our study was a pragmatic, open, multicenter, 
parallel-group, randomized, controlled trial. The 
North West London Research Ethics Committee 
approved the study protocol, which is available 
with the full text of this article at NEJM.org. The 
United Kingdom National Institute for Health 
Research (NIHR) funded the study and convened 
a trial steering committee and independent data 
monitoring and ethics committee. The Clinical 
Trials Unit at the United Kingdom Intensive Care 
National Audit and Research Centre (ICNARC) 
managed the study (for details, see the Supple-
mentary Appendix, available at NEJM.org). Ed-
wards Lifesciences loaned monitors and provided 
training and technical support but had no other 
role in the study.
Sites and Patients
The study was conducted in English NHS hospi-
tals that did not routinely use EGDT that includ-
ed continuous ScvO2 monitoring. Adults (≥18 years 
of age) were eligible if within 6 hours after presen-
tation to the emergency department they had a 
known or presumed infection, two or more criteria 
of the systemic inflammatory response syndrome,16 
and either refractory hypotension (systolic blood 
pressure, <90 mm Hg; or mean arterial pressure, 
<65 mm Hg, despite resuscitation with at least 
1 liter of intravenous fluids within 60 minutes) or 
hyperlactatemia (blood lactate level, ≥4 mmol 
per liter) and did not meet any exclusion criteria 
(see the Methods section in the Supplementary 
Appendix).
Randomization had to be completed within 2 
hours after the patient met the inclusion criteria. 
All patients provided written informed consent, 
or consent was granted through an agreement 
with a personal or professional consultee or in-
dependent clinician.17 Patients were assigned in 
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a 1:1 ratio by means of 24-hour telephone ran-
domization to receive either EGDT or usual care. 
Study-group assignment was performed by 
means of randomized permuted blocks, with 
variable block lengths of 4, 6, and 8, and strati-
fied according to site. In all study patients, anti-
microbial drugs were initiated before random-
ization.
Study Interventions
After randomization, the usual-care group con-
tinued to receive monitoring, investigations, and 
treatment as determined by the treating clini-
cians, whereas the EGDT group started the resus-
citation protocol (Fig. S1 in the Supplementary 
Appendix). For the latter, during the first hour, 
which was defined as the next whole hour (e.g., 
if randomization was performed at 9:24, then by 
11 o’clock), a central venous catheter capable of 
continuous ScvO2 monitoring was placed. The re-
suscitation protocol was followed for 6 hours (in-
tervention period) with personnel involved and 
treatment location decided according to the site. 
At least one trained staff member was available 
throughout the intervention period. Key staff 
members were trained before the initiation of re-
cruitment at each site. All other treatment, dur-
ing the intervention period and after, was at the 
discretion of the treating clinicians. Blinding to 
study-group assignment was not possible. Dur-
ing the intervention period, data were collected 
prospectively for the EGDT group and retrospec-
tively for the usual-care group to avoid the influ-
ence of data collection on treatment delivery.
Outcome Measures
The primary clinical outcome was all-cause mor-
tality at 90 days. Secondary outcomes were the 
score on the Sequential Organ Failure Assess-
ment (SOFA)18 at 6 hours and 72 hours; receipt of 
advanced cardiovascular, advanced respiratory, 
or renal support and the number of days in the 
first 28 days after randomization that were free 
from such support19; length of stay in the emer-
gency department, intensive care unit (ICU), and 
hospital; duration of survival; all-cause mortality 
at 28 days, at hospital discharge, and at 1 year; and 
health-related quality of life (as measured on the 
European Quality of Life–5 Dimensions [EQ-5D] 
five-level questionnaire), resource use, and costs 
at 90 days and 1 year. Adverse events were moni-
tored up to 30 days. All definitions are provided 
in the Supplementary Appendix.
Statistical Analysis
Using the ICNARC Case Mix Program Data-
base,20 we estimated that 90-day mortality would 
be 40% in the usual-care group. On the basis of 
this estimation, we calculated that an enrollment 
of 1260 patients would have a power of 80% to 
detect a relative reduction of 20% in risk (abso-
lute risk reduction, 8 percentage points) in the 
EGDT group, allowing for a loss to follow-up or 
withdrawal of 6%.21
All analyses were performed according to the 
intention-to-treat principle and were prespecified 
in the statistical analysis plan.22 A P value of less 
than 0.05 was considered to indicate statistical 
significance. All tests were two-sided with no 
adjustment for multiple comparisons. Continu-
ous variables are reported as means and standard 
deviations or medians and interquartile ranges. 
Categorical variables are reported as proportions.
We used Fisher’s exact test to compare between-
group differences in the primary outcome. Rela-
tive and absolute reductions in risk are reported 
with 95% confidence intervals without adjustment. 
Secondary analyses of the primary outcome in-
cluded odds ratio with adjustment for Mortality 
in Emergency Department Sepsis (MEDS) score 
components, sensitivity analyses for missing data, 
learning-curve analysis, and adherence-adjusted 
analysis. We conducted prespecified subgroup 
analyses by testing interactions between the ef-
fect of EGDT and the degree of protocolized care 
(in the usual-care group), age, MEDS score,23 
SOFA score, and the time from presentation at 
the emergency department to randomization.
In the cost-effectiveness analysis, we reported 
quality-adjusted life-years (QALYs) by combining 
survival data with quality-of-life scores at 90 days 
and estimated incremental net benefits by valuing 
incremental QALYs at the recommended thresh-
old for a QALY gain (£20,000 [U.S. $28,430]) and 
then subtracting the incremental costs from this 
value.24 Stata/SE software, version 13.0, was used 
for all analyses. (Details about methods are pro-
vided in the Statistical Analysis section in the 
Supplementary Appendix.)
R esult s
Study Patients
From February 16, 2011, to July 24, 2014, we 
screened 6192 patients at 56 sites (including 29% 
that are teaching hospitals), which resulted in 
the enrollment of 1260 patients (Tables S1 and 
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S2 and Fig. S2 and S3 in the Supplementary Ap-
pendix). Four patients requested complete with-
drawal and five were ineligible, which left 1251 
patients in the initial analysis (625 in the EGDT 
group and 626 in the usual-care group). Eight 
patients withdrew before 90 days, which left 
1243 patients in the analysis of outcomes (623 in 
the EGDT group and 620 in the usual-care group) 
(Fig. 1, and Table S3 in the Supplementary Ap-
pendix). The two study groups were well matched 
at baseline (Table 1, and Table S4 in the Supple-
mentary Appendix).
The criterion for refractory hypotension was 
met in 338 patients (54.1%) in the EGDT group 
and 348 patients (55.6%) in the usual-care group, 
and the criterion for hyperlactatemia was met in 
409 patients (65.4%) and 399 patients (63.7%), 
respectively. The intravenous-fluid volume before 
randomization was similar in the two groups, as 
were median times from presentation at the 
emergency department until inclusion criteria 
were met and until randomization. Only about 
two thirds of patients in either group were deemed 
likely to be admitted to the ICU from the emer-
gency department if they were not enrolled in 
the study; those deemed unlikely to be admitted 
were less severely ill. The sites of infection (most 
commonly lung) were well balanced in the two 
groups. All patients received antimicrobial drugs 
before randomization.
Adherence to the Protocol
Most patients in the EGDT group underwent 
timely insertion of a central venous catheter capa-
ble of continuous ScvO2 monitoring. Two cathe-
ters that were inserted in error in the usual-care 
group were not used for monitoring ScvO2 (Table 2, 
and Table S5 in the Supplementary Appendix). In 
the EGDT group, reasons for failure of insertion 
were as follows: patient no longer met inclusion 
criteria or met exclusion criteria (22 patients), 
there was a lapse in the process of care (lack of 
equipment, staff, beds, communication, or error) 
(20 patients), there were technical difficulties or 
problems with a patient (18 patients), there was a 
decision by a clinician (9 patients), or the patient 
declined to have a catheter inserted but did not 
withdraw from the trial (5 patients); in 4 patients, 
no reason was provided, and 2 patients died be-
fore catheter insertion. The mean (±SD) first 
ScvO2 value recorded (at hour 1) was 70±12% 
(Fig. S4 in the Supplementary Appendix). Stan-
dard central venous catheters were not mandated 
but were placed in 50.9% of the patients in the 
usual-care group, and ScvO2 was measured from 
aspirated blood samples in 6 patients. Arterial 
catheters were also not mandated but were placed 
in most patients.
EGDT was stopped prematurely in 21 patients 
(median time to cessation, 3 hours) because 
active treatment was withdrawn (9 patients), the 
patient was no longer considered to have sepsis 
(5 patients), or EGDT was terminated in error 
(3 patients); in addition, 1 patient was transferred 
to an operating room, 1 patient declined treat-
ment, and no reason was provided for 2 patients. 
Among the 35 patients who died within 6 hours 
(17 in the EGDT group and 18 in the usual-care 
group), 5 in the EGDT group and 6 in the usual-
care group had withdrawal of active treatment. 
Adherence to EGDT ranged from 86 to 95%, 
depending on the method of assessment (Fig. S5 
in the Supplementary Appendix).
Intervention Period
During the 6-hour intervention period, patients 
in the EGDT group received more intravenous 
fluids than did patients in the usual-care group 
(Table 2). Hourly fluid volume decreased over the 
6 hours, but patients in the usual-care group re-
ceived a larger initial volume (Fig. S6 in the Sup-
plementary Appendix). Crystalloids were admin-
istered more frequently than colloids in the two 
groups. More patients in the EGDT group than in 
the usual-care group received vasopressors and 
dobutamine. Although more patients in the EGDT 
group received red-cell transfusions, larger vol-
umes were transfused in the usual-care group. 
During the 6-hour intervention period, administra-
tion of platelets and fresh-frozen plasma was simi-
lar in the two groups, although the volume of 
each was higher in the EGDT group (Table 2). At 
6 hours, values for central venous pressure, mean 
arterial pressure, systolic blood pressure, and hemo-
globin were similar in the two groups among pa-
tients in whom they were measured, which hap-
pened with greater frequency in the EGDT group 
(Table S6 in the Supplementary Appendix).
After the Intervention Period
Between 6 and 72 hours, the numbers of patients 
in the two groups receiving intravenous fluids 
The New England Journal of Medicine 
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1260 Underwent randomization
6192 Patients met inclusion criteria
2415 Met exclusion criteria
841 Had treating physician who deemed aggressive care unsuitable
794 Had do-not-resuscitate order
167 Were not able to start EGDT ≤1 hr after randomization or 
complete 6 hr of EGDT
142 Required immediate surgery
74 Had contraindication to central venous catheterization
58 Had major cardiac arrhythmia
57 Had hemodynamic instability from active gastrointestinal
hemorrhage
57 Were transferred from another in-hospital setting
42 Had seizure
25 Had stroke
25 Had acute coronary syndrome
24 Had drug overdose
23 Had acute pulmonary edema
16 Had advance directives restricting implementation of EGDT
16 Were <18 yr of age
15 Were known to have a history of AIDS
15 Were previously enrolled in ProMISe
8 Had injury from burn or trauma
6 Had status asthmaticus
5 Had contraindication to blood transfusion
5 Were known to be pregnant
2517 Were eligible but did not undergo randomization
995 Had study logistic issues
449 Were excluded by clinician
354 Declined to give consent
343 Had delayed referral
239 Were unable to give consent
112 Had other reasons
25 Did not provide reason
630 Were assigned to receive EGDT
630 Were assigned to receive
usual resuscitation
625 Were eligible for analysis
3 Requested removal of all data
2 Were ineligible
626 Were eligible for analysis
1 Requested removal of all data
3 Were ineligible
623 Were included in primary outcome
analysis
2 Withdrew in <90 days
620 Were included in primary outcome
analysis
6 Withdrew in <90 days
356 (81% of those eligible for follow-up)
Returned EQ-5D questionnaire
at 90 days
339 Had complete data
354 (81% of those eligible for follow-up)
Returned EQ-5D questionnaire
at 90 days
332 Had complete data
Figure 1. Enrollment and Outcomes.
AIDS denotes acquired immunodeficiency syndrome, EGDT early, goal-directed therapy, and EQ-5D European Quality 
of Life–5 Dimensions.
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Table 1. Characteristics of the Patients at Baseline.*
Characteristic
EGDT  
(N = 625)
Usual Care 
(N = 626)
Age — yr 66.4±14.6 64.3±15.5
Male sex — no. (%) 356 (57.0) 367 (58.6)
Refractory hypotension — no. (%) 338 (54.1) 348 (55.6)
Systolic blood pressure — mm Hg 77.7±11.0 78.4±10.2
Mean arterial pressure — mm Hg 58.8±15.8 59.0±10.7
Hyperlactatemia — no. (%) 409 (65.4) 399 (63.7)
Blood lactate level — mmol/liter 7.0±3.5 6.8±3.2
Intravenous fluids administered†
Before hospitalization until randomization — no./total no. (%) 612/625 (97.9) 606/625 (97.0)
Median total before hospitalization until randomization (IQR) — ml 1950 (1000–2500) 2000 (1000–2500)
Supplemental oxygen — no./total no. (%)‡ 397/539 (73.7) 407/542 (75.1)
Median time from presentation in emergency department to randomization (IQR) — hr 2.5 (1.8–3.5) 2.5 (1.8–3.5)
Patient would have been admitted directly from emergency department to ICU if not  
enrolled in study
Yes
Patients — no. (%) 419 (67.0) 427 (68.2)
APACHE II score§ 20±6.9 19.0±7.1
No
Patients — no. (%) 206 (33.0) 199 (31.8)
APACHE II score§ 15.0±6.1 15.8±6.5
APACHE II score§ 18.7±7.1 18.0±7.1
MEDS score¶ 8.0±3.4 7.9±3.3
SOFA score‖ 4.2±2.4 4.3±2.4
Severe condition in medical history — no./total no. (%)** 181/622 (29.1) 161/626 (25.7)
Site of infection — no. (%)
Lungs 228 (36.5) 207 (33.1)
Abdomen 40 (6.4) 51 (8.1)
Blood 97 (15.5) 86 (13.7)
Central nervous system 12 (1.9) 9 (1.4)
Soft tissue 39 (6.2) 39 (6.2)
Urinary tract 108 (17.3) 117 (18.7)
Other 21 (3.4) 37 (5.9)
No sepsis†† 4 (0.6) 3 (0.5)
Unknown 76 (12.2) 77 (12.3)
Change from initial antimicrobial drugs by 72 hr — no./total no. (%) 359/615 (58.4) 342/617 (55.4)
* Plus–minus values are means ±SD. There were no significant differences between the two groups except for age (P = 0.01). EGDT denotes 
early, goal-directed therapy, and IQR interquartile range.
† Intravenous fluids include crystalloids and colloids measuring more than 20 ml in volume and all blood products.
‡ The use of supplemental oxygen was based on the fraction of inspired oxygen.
§ Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores indicating greater severity 
of illness. The APACHE II score was calculated on the basis of the last recorded data before randomization.
¶ Scores on the Mortality in Emergency Department Sepsis (MEDS) scale range from 0 to 27, with higher scores indicating greater severity of 
illness. The MEDS score was calculated on the basis of the last recorded data before randomization.
‖ Scores on the Sequential Organ Failure Assessment (SOFA) range from 0 to 24, with higher scores indicating a greater degree of organ 
failure. The SOFA score was calculated on the basis of the last recorded data before randomization. The SOFA renal score was based on 
the plasma creatinine level only and did not include urine output.
**  Severe conditions in the medical history were defined according to the APACHE II score.
††  The lack of sepsis was confirmed after randomization.
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were similar, but patients in the usual-care group 
received larger volumes. More patients in the 
EGDT group received intravenous colloids, but 
overall volumes were similar in the two groups. 
The number of patients receiving intravenous 
crystalloids was similar in the two groups, but 
volumes were larger in the usual-care group. The 
number of patients receiving red-cell transfu-
sions was higher in the EGDT group, but vol-
umes were larger in the usual-care group. The 
use of vasopressors and dobutamine remained 
higher in the EGDT group. Although the num-
bers of patients receiving platelets and fresh-fro-
zen plasma were similar in the two groups, the 
volume of platelets was larger in the EGDT group, 
whereas the volume of fresh-frozen plasma was 
higher in the usual-care group (Table 2, and Ta-
ble S7 in the Supplementary Appendix). At 72 
Table 2. Interventions Delivered during and after the 6-Hour Intervention Period.*
Intervention Hour 0 to 6 Hour >6 to 72
EGDT  
(N = 625)
Usual Care  
(N = 626)
EGDT  
(N = 608)
Usual Care  
(N = 607)
Supplemental oxygen — no./total no. (%) 558/623 (89.6) 557/625 (89.1) 520/603 (86.2) 515/603 (85.4)
Insertion of central venous catheter with ScvO2 
monitoring capability
Patients — no./total no. (%) 545/624 (87.3) 2/625 (0.3) NA NA
Before hour 1 — no./total no. (%) 459/543 (84.5) NA NA NA
Insertion of any central venous catheter
Patients — no./total no. (%) 575/624 (92.1) 318/625 (50.9) NA NA
Median time from randomization to insertion 
(IQR) — hr
1.1 (0.8–1.5) 1.4 (0.6–2.9) NA NA
Insertion of arterial catheter
Patients — no./total no. (%) 462/623 (74.2) 389/625 (62.2) NA NA
Median time from randomization to insertion 
(IQR) — hr
1.1 (0.4–1.9) 1.0 (0.2–1.9) NA NA
Median total intravenous fluids (IQR) — ml† 2000 (1150–3000) 1784 (1075–2775) 3623 (1800–6060) 3981 (1895–6291)
Intravenous colloids
Patients — no./total no. (%)† 197/623 (31.6) 180/625 (28.8) 171/603 (28.4) 150/603 (24.9)
Median volume (IQR) — ml 1000 (500–1500) 750 (500–1000) 750 (500–1750) 750 (500–1500)
Intravenous crystalloids
Patients — no./total no. (%)† 584/623 (93.7) 597/625 (95.5) 537/603 (89.1) 543/603 (90.0)
Median volume (IQR) — ml 1750 (999–2750) 1500 (900–2380) 3403 (1576–5647) 3694 (1832–5911)
Vasopressor — no./total no. (%) 332/623 (53.3) 291/625 (46.6) 349/603 (57.9) 317/603 (52.6)
Dobutamine — no./total no. (%) 113/623 (18.1) 24/625 (3.8) 107/603 (17.7) 39/603 (6.5)
Red-cell transfusion
Patients — no./total no. (%) 55/623 (8.8) 24/625 (3.8) 76/603 (12.6) 51/603 (8.5)
Median volume (IQR) — ml 309 (285–577) 535 (305–607) 351 (291–579) 552 (317–620)
Platelets
Patients — no./total no. (%) 11/623 (1.8) 10/625 (1.6) 23/603 (3.8) 25/603 (4.1)
Median volume (IQR) — ml 315 (200–340) 180 (163–342) 274 (182–366) 187 (172–357)
Fresh-frozen plasma
Patients — no./total no. (%) 15/623 (2.4) 14/625 (2.2) 28/603 (4.6) 30/603 (5.0)
Median volume (IQR) — ml 1007 (539–1095) 793 (526–1085) 587 (483–1000) 846 (528–1057)
ICU admission — no./total no. (%) 551/625 (88.2) 467/626 (74.6) NA NA
Median time from randomization to ICU  
admission (IQR) — hr
1.2 (0.4–2.8) 1.2 (0.3–2.8) NA NA
* ICU denotes intensive care unit, NA not applicable, and ScvO2 central venous oxygen saturation.
† Included in this category is the administration of more than 20 ml of an intravenous fluid.
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hours, physiological, biochemical, and SOFA val-
ues were similar in the two groups (Table S8 in 
the Supplementary Appendix).
Primary Outcome
Mortality at 90 days was not significantly differ-
ent in the two groups, with deaths reported in 
184 of 623 patients (29.5%) in the EGDT group 
versus 181 of 620 patients (29.2%) in the usual-
care group, with an unadjusted relative risk in 
the EGDT group of 1.01 (95% CI, 0.85 to 1.20; 
P = 0.90), for an absolute risk reduction of −0.3 
percentage points (95% CI, −5.4 to 4.7). After ad-
justment for baseline characteristics, the odds 
ratio was 0.95 (95% CI, 0.74 to 1.24; P = 0.73) 
(Table 3). Sensitivity analyses for patients with a 
missing primary outcome (2 in the EGDT group 
and 6 in the usual-care group) showed relative 
risks ranging from 0.99 to 1.03. There was no 
evidence of a learning-curve effect (P = 0.56). In 
the adherence-adjusted analysis, the relative risk 
was 1.02 (95% CI, 0.78 to 1.32; P = 0.90) (Table S9 
and Fig. S7 in the Supplementary Appendix).
Secondary Outcomes
The mean SOFA score at 6 hours, the proportion 
of patients receiving advanced cardiovascular 
support, and the median length of stay in the 
ICU were significantly greater in the EGDT group 
than in the usual-care group. No other secondary 
Table 3. Study Outcomes.*
Outcome
EGDT 
(N = 625)
Usual Care 
(N = 626)
Incremental Effect  
(95% CI) P Value
Clinical effectiveness
Primary outcome: death from any cause at 90 days — 
no./total no. (%)
184/623 (29.5) 181/620 (29.2)
Relative risk 1.01 (0.85 to 1.20) 0.90†
Absolute risk reduction — percentage points −0.3 (−5.4 to 4.7)
Unadjusted odds ratio 1.02 (0.80 to 1.30)
Adjusted odds ratio 0.95 (0.74 to 1.24) 0.73
Secondary outcomes
SOFA score‡
At 6 hr 6.4±3.8 5.6±3.8 0.8 (0.5 to 1.1)§ <0.001
At 72 hr 4.0±3.8 3.7±3.6 0.4 (−0.0 to 0.8)§ 0.056
Receipt of advanced cardiovascular support —  
no./total no. (%)
230/622 (37.0) 190/614 (30.9) 1.19 (1.02 to 1.40)¶ 0.026†
Receipt of advanced respiratory support —  
no./total no. (%)
179/620 (28.9) 175/615 (28.5) 1.01 (0.85 to 1.21)¶ 0.90†
Receipt of renal support — no./total no. (%) 88/620 (14.2) 81/614 (13.2) 1.08 (0.81 to 1.42)¶ 0.62†
Days free from advanced cardiovascular support up 
to 28 days
20.3±11.9 20.6±11.8 −0.3 (−1.5 to 1.0)§ 0.63
Days free from advanced respiratory support up to 
28 days
19.6±12.1 19.8±12.0 −0.2 (−1.5 to 1.1)§ 0.78
Days free from renal support up to 28 days 20.6±12.1 20.6±11.9 0.0 (−1.3 to 1.3)§ 0.97
Median length of stay in emergency department 
(IQR) — hr
1.5 (0.4 to 3.1) 1.3 (0.4 to 2.9) 0.34‖
Median length of stay in ICU (IQR) — days 2.6 (1.0 to 5.8) 2.2 (0.0 to 5.3) 0.005‖
Median length of stay in hospital (IQR) — days 9 (4 to 21) 9 (4 to 18) 0.46‖
Death from any cause — no./total no. (%)
At 28 days 155/625 (24.8) 152/621 (24.5) 1.01 (0.83 to 1.23)¶ 0.90†
0.95 (0.73 to 1.25)** 0.73
At hospital discharge 160/625 (25.6) 154/625 (24.6) 1.04 (0.86 to 1.26)¶ 0.74†
0.98 (0.75 to 1.29)** 0.90
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outcomes were significantly different (Table 3, 
and Table S10 in the Supplementary Appendix). 
There was no significant difference in the dura-
tion of survival between the two groups (P = 0.63 
by the log-rank test; adjusted hazard ratio, 0.94, 
95% CI, 0.79 to 1.11; P = 0.46) (Fig. 2). Mean EQ-5D 
scores and QALYs were similar in the two groups. 
The average cost was higher in the EGDT group 
(£12,414 [U.S. $17,647]) than in the usual-care 
group (£11,424 [U.S. $16,239]), but the difference 
was not significant (P = 0.26) (Table 3, and Tables 
S11 through S16 and Fig. S8 in the Supplemen-
tary Appendix). The incremental net benefit for 
EGDT as compared with usual care was negative 
and similar across prespecified subgroups and 
alternative scenarios that were considered in sen-
sitivity analyses (Tables S17 and S18 and Fig. S9 in 
the Supplementary Appendix). The probability 
that EGDT was cost-effective was below 20% 
(Fig. S10 in the Supplementary Appendix).
Table 3. (Continued.)
Outcome
EGDT 
(N = 625)
Usual Care 
(N = 626)
Incremental Effect  
(95% CI) P Value
Cost-effectiveness
Health-related quality of life on EQ-5D at  
90 days†† 0.609±0.319 0.613±0.312 −0.004 (−0.051 to 0.044)§ 0.88
Quality-adjusted life-yr up to 90 days 0.054±0.048 0.054±0.048 −0.001 (−0.006 to 0.005)§ 0.85
Costs up to 90 days 0.26
Pounds 12,414±14,970 11,424±15,727 989 (−726 to 2,705)§
Dollars  17,647±21,280 16,239±22,356 1,406 (−1,032 to 3,845)§
Incremental net benefit up to 90 days‡‡ 0.25
Pounds NA NA −1,000 (−2,720 to 720)§
Dollars NA NA −1,422 (−3,866 to 1,023)§
Serious adverse events — no. (%) 30 (4.8) 26 (4.2) 1.16 (0.69 to 1.93)¶ 0.58†
*  All values for the incremental effect are for the EGDT group as compared with the usual-care group. Plus–minus values are means ±SD.
†  The P value was calculated with the use of Fisher’s exact test.
‡  Renal scores on the Sequential Organ Failure Assessment (SOFA) were based on the plasma creatinine level only. Patients in whom the 
variables for SOFA renal and SOFA coagulation scores were not recorded between randomization and 6 hours had these values carried 
forward from baseline, if recorded. Scores for 181 patients who died or were discharged before 48 hours (84 in the EGDT group and 97 in 
the usual-care group) were not included in SOFA score at 72 hours.
§ This value is the difference between the means.
¶ This value is the relative risk.
‖ The P value was calculated by means of the Wilcoxon rank-sum test.
** This value is the adjusted odds ratio.
†† Scores on the European Quality of Life–5 Dimensions (EQ-5D) questionnaire range from 0 (death) to 1 (perfect health), with higher 
scores indicating a better quality of life.
‡‡ The incremental net benefit was calculated according to methods of the National Institute for Health and Care Excellence (NICE) by multi-
plying the mean gain or loss in quality-adjusted life-years by £20,000 ($28,430) and subtracting from this value the incremental cost. The 
currency conversion factor that was used was £1 equals $1.4215.
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Figure 2. Kaplan–Meier Survival Estimates.
Shown is the probability of survival for patients with severe sepsis receiving 
early, goal-directed therapy (EGDT) and those receiving usual care at 90 days.
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Subgroup Analyses
There was no significant difference regarding 
the effect of EGDT according to prespecified 
subgroups as defined by the degree of proto-
colized care used in the usual-care group, age, 
MEDS score, SOFA score, or time from presenta-
tion at the emergency department to randomiza-
tion (P = 0.39 to 0.72 for interaction) (Table S9 
and Fig. S11 in the Supplementary Appendix).
Serious Adverse Events
At least one serious adverse event was reported in 
30 patients (4.8%) in the EGDT group and 26 
patients (4.2%) in the usual-care group (P = 0.58) 
(Table 3, and Table S19 in the Supplementary Ap-
pendix). Four serious adverse events were report-
ed as being related to EGDT (two cases of pulmo-
nary edema and one of arrhythmia, which were 
deemed to be probably related, and one case of 
myocardial ischemia, which was deemed to be 
definitely related), as compared with four events 
(in three patients) related to usual care (two cases 
of pneumothorax and one case of pulmonary 
edema, which were deemed to be probably relat-
ed, and one case of ventricular fibrillation, which 
was deemed to be definitely related).
Discussion
In our study involving adults with early signs of 
septic shock who presented to emergency depart-
ments in England, there was no significant dif-
ference in mortality at 90 days among those re-
ceiving 6 hours of EGDT and those receiving 
usual resuscitation. Although the overall rate of 
death in the usual-care group was lower than an-
ticipated (29% rather than 40%), it is unlikely 
that patients in the EGDT group would have a 
relative reduction of more than 15% in risk. The 
effect of EGDT was not significantly different in 
prespecified subgroups. More patients receiving 
EGDT were admitted to and spent more days in 
the ICU. Treatment intensity was greater in the 
EGDT group, driven by adherence to the protocol 
and indicated by the increased use of central ve-
nous catheters, intravenous fluids, vasoactive 
drugs, and red-cell transfusions. Increased inten-
sity was reflected by significantly higher SOFA 
scores and more days of receiving advanced car-
diovascular support. There were no significant 
differences in any other secondary outcomes, in-
cluding health-related quality of life, which was 
substantially poorer in this severely ill group of 
patients (0.60) than in the general population 
matched for age and sex (0.80).25 On average, the 
use of EGDT increased costs, and given similar 
QALYs in the two groups, the probability that 
EGDT was cost-effective was below 20%.
Our study was set in a real-world context and 
in a large, representative, mixed sample of ap-
proximately one quarter of NHS hospitals in 
England. Site setup was rapid, and the study re-
cruited the full 1260 patients over a shorter time 
period than those of the two similar studies in 
the United States12 and Australasia.13 This factor 
minimized the potential for other changes in 
clinical practice to affect outcomes. Unlike previ-
ous studies, our study reports on quality of life and 
cost-effectiveness at 90 days. Loss to follow-up 
was low, and all analyses were conducted ac-
cording to a prespecified statistical analysis plan 
and included adjusted analyses to address the 
degree of adherence to EGDT and the possibility 
of the existence of a learning curve for its delivery.
Our study has several limitations. As in all 
studies that enroll patients presenting to emer-
gency departments, recruitment was more chal-
lenging on weekends and during out-of-office 
hours; overall, only one third of eligible patients 
were recruited, although exclusion from the study 
by a clinician was rare. The intervention could 
not be blinded, but the risk of bias was mini-
mized through central randomization to ensure 
the concealment of study-group assignments and 
the use of a primary outcome that was not sub-
ject to observer bias. Since the rate of death was 
lower than anticipated, our study data may not 
apply to settings with higher mortality.
Unlike Rivers et al., in their 2001 study, we 
did not observe a significant reduction in hospi-
tal mortality with the use of EGDT. Many aspects 
of initial sepsis management have changed dur-
ing the past 15 years, as can be seen in compar-
ing the usual-care groups. In our study, as com-
pared with the study by Rivers et al., mortality 
was substantially reduced, randomization oc-
curred later, patients appeared to be less sick at 
baseline (with lower blood lactate levels and 
Acute Physiology and Chronic Health Evaluation 
[APACHE] II scores), and all patients received 
antibiotics before randomization. In addition, 
our patients received much lower volumes of 
intravenous fluids and more vasoactive drugs 
(Table S20 in the Supplementary Appendix).
The level of adherence to EGDT was good and 
was equivalent to adherence levels in the ProCESS12 
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and ARISE13 trials and higher than reported rates 
of compliance with the SSC guidelines.26 Most 
outcomes were similar to those reported in the 
ProCESS and ARISE trials, although the rate of 
death at 90 days that was reported in our study was 
lower than that in the ProCESS trial but higher than 
that in the ARISE trial. Of note, a higher proportion 
of patients in our study than in the ProCESS and 
ARISE trials met both of the two inclusion crite-
ria — refractory hypotension and hyperlactate-
mia (Table S21 in the Supplementary Appendix) 
— a factor that is associated in our national ICU 
database with a doubling of hospital mortality 
(Table S22 in the Supplementary Appendix).
In conclusion, our results suggest that tech-
niques used in usual resuscitation have evolved 
over the 15 years since the landmark study by 
Rivers et al.9 In our study, NHS hospitals achieved 
levels of in-hospital survival in patients receiving 
usual care that were similar to those achieved 
with EGDT in the earlier study for patients with 
septic shock who were identified early and re-
ceived intravenous antibiotics and adequate fluid 
resuscitation. The addition of continuous ScvO2 
monitoring and strict protocolization did not 
improve outcomes in the EGDT group. Our re-
sults complete the planned trio of studies of 
EGDT, all of which showed that EGDT was not 
superior to usual care.
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